**RILUTEK (riluzole)**

Effective Date: 1/28/14

Date Developed: 1.28.14 by Robert Sterling, MD

Last Approval Date: 01.26.16, 01.24.17

**Rilutek** is used in the palliative treatment of amyotrophic lateral sclerosis (ALS) to extend survival and/or time to tracheostomy

**Authorization:** patients diagnosed with ALS

**Dosing:** 50mg every 12 hours, one hour before or two hours after a meal; little or no benefit to increased doses

**PRECAUTIONS:** use with caution in patients with liver disease; neutropenia; hypersensitivity pneumonitis; nausea; abdominal pain; constipation or diarrhea; methemoglobinemia; asthenia

**DRUG INTERACTIONS:** none reported

**REFERENCES**


**Revision History:**

Date Reviewed/No Updates: 01.13.15 by C. Sanders, MD
Date Approved by P&T Committee: 01.27.15

Date Reviewed/No Updates: 01.26.16 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 01.26.16

Date Reviewed/No Updates: 01.24.17 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 01.24.17
<table>
<thead>
<tr>
<th>Revision Date</th>
<th>Content Revised (Yes/No)</th>
<th>Contributors</th>
<th>Review/Revision Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/24/17</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
</tbody>
</table>